Filtered By:
Condition: Cholesterol
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 572 results found since Jan 2013.
Inclisiran: A Novel Small Interfering RNA Drug for LDL Reduction
This article is protected by copyright. All rights reserved.PMID:35279835 | DOI:10.1002/jcph.2045
Source: The Journal of Clinical Pharmacology - March 13, 2022 Category: Drugs & Pharmacology Authors: Kimberly W Smith C Michael White Source Type: research
Cancers, Vol. 14, Pages 3255: A Novel Role of SMG1 in Cholesterol Homeostasis That Depends Partially on p53 Alternative Splicing
Thompson
SMG1, a phosphatidylinositol 3-kinase-related kinase (PIKK), essential in nonsense-mediated RNA decay (NMD), also regulates p53, including the alternative splicing of p53 isoforms reported to retain p53 functions. We confirm that SMG1 inhibition in MCF7 tumor cells induces p53β and show p53γ increase. Inhibiting SMG1, but not UPF1 (a core factor in NMD), upregulated several cholesterol pathway genes. SMG1 knockdown significantly increased ABCA1, a cholesterol efflux pump shown to be positively regulated by full-length p53 (p53α). An investigation of RASSF1C, an NMD tar...
Source: Cancers - July 2, 2022 Category: Cancer & Oncology Authors: Muyang Li Fredrick Philantrope Alexandra Diot Jean-Christophe Bourdon Patricia Thompson Tags: Article Source Type: research
Oridonin attenuates low shear stress-induced endothelial cell dysfunction and oxidative stress by activating the nuclear factor erythroid 2-related factor 2 pathway
CONCLUSIONS: In conclusion, the results of the present study suggested that oridonin may ameliorate LSS-induced EC dysfunction and oxidative stress by activating NRF2, thereby attenuating AS.PMID:35799227 | DOI:10.1186/s12906-022-03658-2
Source: Atherosclerosis - July 7, 2022 Category: Cardiology Authors: Zhipeng Chen Heqian Liu Xiaoqi Zhao Subinur Mamateli Cheng Liu Lei Wang Jing Yu Yutong Liu Jing Cai Tong Qiao Source Type: research
PACS-2 deficiency in tubular cells aggravates lipid-related kidney injury in diabetic kidney disease
CONCLUSIONS: PACS-2 has a protective role against lipid-related kidney injury in DKD through SOAT1/SREBPs signaling.PMID:36138342 | DOI:10.1186/s10020-022-00545-x
Source: Molecular Medicine - September 22, 2022 Category: Molecular Biology Authors: Chanyue Zhao Li Li Chenrui Li Chengyuan Tang Juan Cai Yu Liu Jinfei Yang Yiyun Xi Ming Yang Na Jiang Yachun Han Yan Liu Shilu Luo Li Xiao Lin Sun Source Type: research
A Novel Angiogenic Effect of PCSK9- Regulated Genes
CONCLUSION: PCSK9 might play an essential role in angiogenesis, unlike its typical role in lipid metabolism, and MMP9, Caspase3, LEFTY1, NODAL, and EGR1 may be involved in the regulation of angiogenesis as critical genes.PMID:36427678 | DOI:10.1016/j.gene.2022.147051
Source: Gene - November 25, 2022 Category: Genetics & Stem Cells Authors: Xiaopeng Zhan Li Jiang Lufeng Wang Jiwen Liu Sheng Kang Haibo Liu Li Lin Source Type: research
Cancers, Vol. 15, Pages 1397: PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
nno
Nicola Maurea
Cancer patients treated with immune checkpoint inhibitors (ICIs) are exposed to a high risk of atherosclerosis and cardiometabolic diseases due to systemic inflammatory conditions and immune-related atheroma destabilization. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key protein involved in metabolism of low-density lipoprotein (LDL) cholesterol. PCSK9 blocking agents are clinically available and involve monoclonal antibodies, and SiRNA reduces LDL levels in high-risk patients and atherosclerotic cardiovascular disease events in multiple patient cohorts. Moreover, PCSK9 induces perip...
Source: Cancers - February 22, 2023 Category: Cancer & Oncology Authors: Vincenzo Quagliariello Irma Bisceglia Massimiliano Berretta Martina Iovine Maria Laura Canale Carlo Maurea Vienna Giordano Andrea Paccone Alessandro Inno Nicola Maurea Tags: Review Source Type: research
Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Pharmaceutics. 2023 Jan 18;15(2):323. doi: 10.3390/pharmaceutics15020323.ABSTRACTDyslipidemia is listed among important cardiovascular disease risk factors. Treating lipid disorders is difficult, and achieving desirable levels of LDL-cholesterol (LDL-C) is essential in both the secondary and primary prevention of cardiovascular disease. For many years, statins became the basis of lipid-lowering therapy. Nevertheless, these drugs are often insufficient due to their side effects and restrictive criteria for achieving the recommended LDL-C values. Even the addition of other drugs, i.e., ezetimibe, does not help one achieve th...
Source: Atherosclerosis - February 25, 2023 Category: Cardiology Authors: Łukasz Wołowiec Joanna Osiak Anna Wo łowiec Aleksandra Wijata El żbieta Grześk Mariusz Kozakiewicz Joanna Banach Alicja Nowaczyk Jacek Nowaczyk Grzegorz Grze śk Source Type: research
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Cancers (Basel). 2023 Feb 22;15(5):1397. doi: 10.3390/cancers15051397.ABSTRACTCancer patients treated with immune checkpoint inhibitors (ICIs) are exposed to a high risk of atherosclerosis and cardiometabolic diseases due to systemic inflammatory conditions and immune-related atheroma destabilization. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key protein involved in metabolism of low-density lipoprotein (LDL) cholesterol. PCSK9 blocking agents are clinically available and involve monoclonal antibodies, and SiRNA reduces LDL levels in high-risk patients and atherosclerotic cardiovascular disease events in m...
Source: Atherosclerosis - March 11, 2023 Category: Cardiology Authors: Vincenzo Quagliariello Irma Bisceglia Massimiliano Berretta Martina Iovine Maria Laura Canale Carlo Maurea Vienna Giordano Andrea Paccone Alessandro Inno Nicola Maurea Source Type: research
Uncovering Tumor-Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma
Adv Sci (Weinh). 2023 Apr 21:e2207010. doi: 10.1002/advs.202207010. Online ahead of print.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with high incidence rates of metastasis and cachexia. High circulating activin A, a homodimer of inhibin βA subunits that are encoded by INHBA gene, predicts poor survival among PDAC patients. However, it still raises the question of whether activin A suppression renders favorable PDAC outcomes. Here, the authors demonstrate that activin A is abundantly detected in tumor and stromal cells on PDAC tissue microarray and mouse PDAC sections. In orthotopic ...
Source: Adv Data - April 21, 2023 Category: Epidemiology Authors: Seok-Yeong Yu Yi Luan Siyuan Tang Amirhossein Abazarikia Rosemary Dong Thomas C Caffrey Michael A Hollingsworth David Oupicky So-Youn Kim Source Type: research
Steep LDL Cholesterol Reductions With ANGPTL3 siRNA in HoFH Steep LDL Cholesterol Reductions With ANGPTL3 siRNA in HoFH
A single injection every 3 months of a novel drug that targets the lipid metabolism enzyme ANGPTL3 resulted in substantial reductions in LDL cholesterol in patients with HoFH in the phase 2 GATEWAY trial.Medscape Medical News
Source: Medscape Cardiology Headlines - June 1, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
